Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.09 +4.3%	$1.58	$0.87 ▼ $6.37	$211.02M	0.86	813,055 shs	753,041 shs
TRVI Trevi Therapeutics	$7.53 +2.7%	$6.63	$2.36 ▼ $8.11	$914.57M	0.58	1.83 million shs	714,697 shs
UPB Upstream Bio	$18.19 +3.9%	$12.29	$5.14 ▼ $29.46	$965.80M	N/A	350,518 shs	253,853 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	-10.31%	+28.21%	+24.22%	+86.92%	-60.82%
TRVI Trevi Therapeutics	+0.14%	-1.08%	+11.91%	+18.42%	+168.50%
UPB Upstream Bio	+5.49%	+12.90%	+52.44%	+104.44%	+1,749,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALEC Alector	4.0968 of 5 stars	3.1	3.0	4.5	3.0	2.5	0.0
TRVI Trevi Therapeutics	3.051 of 5 stars	4.7	1.0	0.0	2.6	2.5	0.0
UPB Upstream Bio	1.7738 of 5 stars	3.5	0.0	0.0	1.5	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.29	Hold	$4.17	99.84% Upside
TRVI Trevi Therapeutics	3.30	Buy	$20.38	170.69% Upside
UPB Upstream Bio	3.00	Buy	$56.50	210.66% Upside

Current Analyst Ratings Breakdown

Latest ALEC, UPB, and TRVI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	TRVI Trevi Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Strong-Buy ➝ Strong-Buy	$29.00 ➝ $27.00
8/8/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $22.00
7/28/2025	ALEC Alector	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$2.50 ➝ $3.50
7/1/2025	TRVI Trevi Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$25.00
6/2/2025	TRVI Trevi Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
6/2/2025	TRVI Trevi Therapeutics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$21.00
5/28/2025	TRVI Trevi Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Buy	$21.00
5/20/2025	TRVI Trevi Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $24.00

(Data available from 8/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$100.56M	2.10	N/A	N/A	$0.70 per share	2.98
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	$1.63 per share	N/A
UPB Upstream Bio	$2.37M	413.70	N/A	N/A	$7.58 per share	2.40

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$119.05M	-$1.16	N/A	N/A	N/A	-142.10%	-112.06%	-26.37%	N/A
TRVI Trevi Therapeutics	-$47.91M	-$0.42	N/A	N/A	N/A	N/A	-41.44%	-38.21%	N/A
UPB Upstream Bio	-$62.81M	N/A	0.00	N/A	N/A	-3,836.58%	-35.90%	-26.26%	N/A

Latest ALEC, UPB, and TRVI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ALEC Alector	-$0.45	-$0.30	+$0.15	-$0.30	$2.76 million	$7.87 million
8/7/2025	Q2 2025	TRVI Trevi Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A
8/6/2025	Q2 2025	UPB Upstream Bio	-$0.61	-$0.74	-$0.13	-$0.74	$0.32 million	$0.94 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
TRVI Trevi Therapeutics	N/A	N/A	N/A	N/A	N/A
UPB Upstream Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.13	3.78	3.78
TRVI Trevi Therapeutics	N/A	22.42	22.42
UPB Upstream Bio	N/A	38.27	38.27

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
TRVI Trevi Therapeutics	95.76%
UPB Upstream Bio	N/A

Insider Ownership

Company	Insider Ownership
ALEC Alector	9.70%
TRVI Trevi Therapeutics	18.30%
UPB Upstream Bio	13.56%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	270	101.21 million	91.39 million	Optionable
TRVI Trevi Therapeutics	20	121.78 million	95.83 million	Optionable
UPB Upstream Bio	38	53.91 million	46.60 million	N/A

ALEC, UPB, and TRVI Headlines

Recent News About These Companies

Upstream Bio (NASDAQ:UPB) Sees Unusually-High Trading Volume - Here's Why

August 12 at 6:12 PM | marketbeat.com

William Blair Lowers Earnings Estimates for Upstream Bio

August 10 at 2:19 AM | americanbankingnews.com

Q3 EPS Estimates for Upstream Bio Cut by William Blair

August 9, 2025 | marketbeat.com

Upstream Bio Second Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

August 8, 2025 | finance.yahoo.com

Upstream Bio (UPB) Q2 R&D Soars 169%

August 6, 2025 | fool.com

Upstream Bio, Inc. reports Q2 results

August 6, 2025 | seekingalpha.com

Upstream Bio Reports Second Quarter 2025 Financial Results and Highlights Continued Progress

August 6, 2025 | globenewswire.com

Upstream Bio (UPB) Expected to Announce Earnings on Tuesday

August 3, 2025 | americanbankingnews.com

Upstream Bio (NASDAQ:UPB) Stock Price Up 8.1% - Still a Buy?

July 31, 2025 | marketbeat.com

Upstream Bio (UPB) Expected to Announce Quarterly Earnings on Tuesday

July 29, 2025 | marketbeat.com

Promising Outlook for Upstream Bio, Inc. as Verekitug Advances in Inflammatory Conditions

July 28, 2025 | tipranks.com

Positive Outlook for Upstream Bio, Inc. Driven by Promising Phase II Study of Verekitug in CRSwNP Treatment

July 28, 2025 | tipranks.com

Upstream Bio Inc. (UPB) Stock Price Today - WSJ

July 25, 2025 | wsj.com

Upstream Bio (NASDAQ:UPB) Trading Up 10% - Still a Buy?

July 25, 2025 | marketbeat.com

Upstream Bio begins phase 2 COPD trial for verekitug

July 10, 2025 | uk.investing.com

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic ...

July 8, 2025 | bakersfield.comB

Upstream Bio Initiates Phase 2 VENTURE Trial for Verekitug in Moderate-to-Severe COPD, Expanding Its Respiratory Portfolio

July 8, 2025 | quiverquant.comQ

Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)

July 8, 2025 | globenewswire.com

UPB Upstream Bio, Inc. - Seeking Alpha

June 28, 2025 | seekingalpha.com

Upstream Bio, Inc.’s Verekitug: A Promising Contender in the TSLPR Antibody Space

June 16, 2025 | tipranks.com

Upstream Bio Stock Gets A Boost As New Lung Inflammation Drug Shows Higher Potency

June 15, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, UPB, and TRVI Company Descriptions

Alector NASDAQ:ALEC

$2.08 +0.09 (+4.25%)

As of 02:05 PM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Trevi Therapeutics NASDAQ:TRVI

$7.53 +0.20 (+2.69%)

As of 02:05 PM Eastern

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase 2b Cough Reduction in IPF with nalbuphine ER (CORAL) clinical trial for treatment of chronic cough in patients with IPF; phase 2a Refractory Chronic Cough Improvement Via NAL ER (RIVER) clinical trial for reducing chronic cough in RCC patients; phase 2 clinical trial in patients with pruritus; phase 2b/3 clinical trial in patients with prurigo nodularis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Upstream Bio NASDAQ:UPB

$18.19 +0.69 (+3.93%)

As of 02:05 PM Eastern

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time